Dose-Dependent Inhibition of Human Platelet Aggregation by Prasugrel and its Interaction With Aspirin in Healthy Subjects
Joseph A. Jakubowski(Indiana Biosciences Research Institute), Kenneth J. Winters(Eli Lilly (United States)), Christopher D. Payne(Eli Lilly (United States)), D. Richard Lachno(Alzheimer's Association), Ying G. Li(Eli Lilly (United States)), Govinda Weerakkody(Eli Lilly (United States)), John T. Brandt(Universitätsklinikum Würzburg), Nagy A. Farid(Eli Lilly (United States)), Hideo Naganuma(Daiichi-Sankyo (Japan))
Cited by 56
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617